Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacin.

New, first-in-class oral antibiotics like zoliflodacin, developed in a public-private partnership, require an optimal introduction strategy while ensuring antibiotic stewardship. Zoliflodacin, given as a single dose for uncomplicated urogenital gonorrhoea, recently demonstrated non-inferiority to ceftriaxone plus azithromycin and safety in a phase 3 randomised controlled trial. Following regulatory approval, zoliflodacin could improve sexually transmitted infection (STI) management and help address the threat of untreatable gonorrhoea, as levels of resistance to current first-line treatments increase.

Gastric perforation secondary to mucormycosis infection in a kidney-pancreas transplant patient. A fatal complication.

Mucormycosis is a rare deep fungal infection that develops mainly in immunosuppressed patients, being unusual the gastrointestinal presentation. The adequate treatment consists in rapid and aggressive surgical debridement, along with initial adjuvant treatment with liposomal amphotericin B. Despite recent advances in the management of this disease, the prognosis is poor, with a high mortality rate.